VVT Med (TSXV: DXI.H) (formerly DXI Capital) announced that it has completed its previously announced acquisition of all of the outstanding securities of V.V.T. Med (VVT) and Exiteam Acquisition (EAC), according to the terms of a definitive agreement dated September 30, 2024.
VVT stated further details regarding the transaction are available in the company’s filing statement dated May 15, 2025, and its news releases dated May 21, 2025, June 30, 2025, and July 16, 2025, which can be found under the company’s profile on SEDAR+ at www.sedarplus.ca.
In connection with the completion of the transaction, the TSX Venture Exchange (TSXV) has conditionally approved the listing of the company’s common shares under the new ticker symbol VVTM. The company shares are expected to begin trading on the TSXV on or about July 30, 2025. A further press release will be issued once trading has commenced. The transaction constituted a reverse takeover (RTO) of the company by VVT under the terms of Policy 5.2 of the TSXV.
In a statement, Erex Tetro, CEO of VVT, commented, “The completion of this transaction marks a pivotal moment for VVT Medical as we transition into the public markets and unlock new opportunities for growth. With our innovative, minimally invasive solutions for varicose vein treatment, we are poised to accelerate adoption in key global markets and deliver greater value to patients, physicians, and our shareholders. This milestone is not just a financial step forward—it is a validation of our vision to redefine vein care.”
Following the transaction, the VVT leadership team is as follows:
- Erez Tetro – CEO and director
- Dor Sneh – CFO and corporate secretary
- Yair Aloni – chairman of the BOD
- Stephen Gledhill – director
- Sophie Galper Komet – director
There are currently 66,311,431 company shares issued and outstanding. Additional details regarding the company’s capitalization can be found in VVT’s filing statement.
